Get started
Author

Justyna Żubrowska

Observed names: J. Zubrowska, J. Żubrowska, Żubrowska Justyna, Żubrowska, Justyna
Observed institution: Holy Cross University
ORCID: 0000-0002-7876-2537
Observed ORCID: 0000-0002-7876-2537
OpenAlex ID: A5024526275
Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
2022 · Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, et al. · Biomedicines · 12
Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study
2025 · Renata Duchnowska, Katarzyna Soter, et al. · The Breast · 8
Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.
2024 · Renata Duchnowska, Katarzyna Soter, et al. · Journal of Clinical Oncology · 7
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study
2025 · Justyna Żubrowska, Małgorzata Pieniążek, et al. · Breast Cancer Research and Treatment · 4
PDF
Relationship of adverse events after combined immunotherapy and treatment outcomes in patients with advanced melanoma: A multicenter experience in Poland.
2023 · Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, et al. · Journal of Clinical Oncology · 4
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
2026 · Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, et al. · The Oncologist · 3
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study
2026 · Justyna Żubrowska, Małgorzata Pieniążek, et al. · Journal of Neuro-Oncology · 2
566P Effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer: A real-world retrospective cohort study from central Europe
2025 · M. Pieniazek, M. Puskulluoglu, et al. · Annals of Oncology · 2
PDF
Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study
2026 · Aleksandra Konieczna, Małgorzata Pieniążek, et al. · The Oncologist · 1
First real-world experience with first-line pembrolizumab and chemotherapy treatment for advanced triple-negative breast cancer in Poland: safety analysis and first survival outcomes from a multicenter cohort
2026 · Małgorzata Pieniążek, Aleksandra Konieczna, et al. · Oncology in Clinical Practice · 1
Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitors
2025 · Łukasz Galus, Daria Tusień Małecka, et al. · Współczesna Onkologia · 1
PDF
First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
2024 · K. Kisielewska, K. Kozak, et al. · EJC Skin Cancer · 1
PDF
Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab.
2023 · Katarzyna Kozak, Pawel Teterycz, et al. · Journal of Clinical Oncology · 1
PDF
Correction to: Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort
2026 · Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, et al. · Supportive Care in Cancer
PDF
Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort
2026 · Kubeczko Marcin, Konieczna Aleksandra, et al. · BMC Cancer
Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort
2026 · Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, et al. · Supportive Care in Cancer
PDF
Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland
2026 · Małgorzata Pieniążek, Katarzyna Świderska, et al. · Clinical & Translational Oncology
PDF
Treatment outcomes with pembrolizumab and chemotherapy in metastatic metaplastic triple-negative breast cancer: Data from a central European cohort.
2026 · Justyna Żubrowska, Malgorzata Podskarbi, et al. · Journal of Clinical Oncology
PDF
Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia.
2026 · Miroslawa Puskulluoglu, Joanna Kiszka, et al. · Journal of Clinical Oncology
PDF
Prognostic value of baseline 18F-FDG PET/CT in first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer.
2026 · Marcin Kubeczko, Miroslawa Puskulluoglu, et al. · Journal of Clinical Oncology
Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.
2026 · Malgorzata Podskarbi, Aleksandra Konieczna, et al. · Journal of Clinical Oncology
Radiotherapy in symptomatic metastatic triple-negative breast cancer treated with first-line pembrolizumab and chemotherapy: A multinational real-world study.
2026 · Marcin Kubeczko, Miroslawa Puskulluoglu, et al. · Journal of Clinical Oncology
Baseline inflammatory indexes and prognosis for progression-free survival in first-line pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer: A Polish multicenter cohort study.
2026 · Malgorzata Pieniazek, Karolina Winsko-Szczęsnowicz, et al. · Journal of Clinical Oncology
Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.
2026 · Aleksandra Konieczna, Malgorzata Meluch, et al. · Journal of Clinical Oncology
Abstract PS5-02-20: Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data
2026 · A. Konieczna, M. Holanek, et al. · Clinical Cancer Research
Works count: 39
Citation count: 47
H-index: 4
I10-index: 1
Year
Topic
Type